Global Bevacizumab Industry is
expected to grow at a higher CAGR in the forecast period. Bevacizumab commonly
known as avastin is used to diagnose malignant glioma. The drug belongs to a
class of drugs called monoclonal antibodies in which the drugs are built around
to work with proteins present on the surface of tumor cells.
Specifically, bevacizumab
reduces tumors by eliminating the formation of new blood vessels that feeds
tumors and supplies them with oxygen. This process is known as angiogenesis which
includes blocking the protein action termed as vascular endothelial growth
factor (VEGF). VEGF plays a crucial role in formation of new blood vessels that
surrounds tumors. Hence, with blocking of VEGF, the tumor growth is said to
stop or control.
View Full Report with TOC @ https://www.millioninsights.com/industry-reports/bevacizumab-market
Avastin is generically names
as bevacizumab and is approved by U.S FDA to treat patients with several types
of colorectal and lung cancers. The route of administration for bevacizumab is
to inject through an IV every 14 to 21 days as prescribed. On detection of no
side-effects, the treatment continues. Patients may experience side-effects
such as delayed wound healing, nosebleeds, high blood pressure, excessive
outflow of protein in urine, high blood pressure, fatigue and headache when
diagnosed alone. Overall the global market for bevacizumab is anticipated to
grow at a higher CAGR in the forecast period.
Global bevacizumab is driven
by factors such as rising incidences of tumor and cancer. Additionally,
sedentary lifestyle leading to acute illness also propels the global
bevacizumab market. Moreover, rising geriatric population is anticipated to
fuel the market growth in the forecast period. However, higher medication cost
is likely to impede the market growth in the forecast period.
Global Bevacizumab Industry
geographically spans North America, Latin America, Europe, Asia-Pacific,
Middle-East and Africa. North America and European market is expected to grow
at a higher CAGR in the forecast period owing to rise in prevalence of cancer
and tumor patients. Moreover, increasing R&D in cancer is also expected to
boost the market growth.
APAC regions such as China,
Japan and Singapore are anticipated to boost the market growth owing to large
consumer base and growing prevalence of cancer patients. Middle-East and
African market is expected to grow at a moderate CAGR in the forecast period
owing to rising medical infrastructure and growing R&D activities in the
global bevacizumab industry. The key
players in the global bevacizumab industry include Pfizer, Biocon, Bionomics,
Genexine, Amgen, Levolta Pharmaceuticals, Enzon Pharmaceuticals, Marsala
Biotech, Mabtech, and Fujifilm Kyowa Kirin Biologics.
Request a Sample
Copy of This Report @ https://www.millioninsights.com/industry-reports/bevacizumab-market/request-sample
Comments
Post a Comment